Cyclin C Antibody [J7J21] | Primary Antibodies

Application: Reactivity: Human, Mouse

Usage Information

Dilution
WB1:1000 IP1:100 IF1:1600 - 1:6400 FCM1:100 - 1:400

Application
WB, IP, IF, FCM

Reactivity
Human, Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
30 kDa

Positive Control	293T cells;A-172 cells;A-204 cells;ACHN cells;HCC1806 cells;K-562 cells;NIH/3T3 cells;C2C12 cells;HCT 116 cells
Negative Control

Datasheet & SDS

Biological Description

Specificity
Cyclin C Antibody [J7J21] detects endogenous levels of total Cyclin C protein.

Clone
J7J21

Synonym(s)
Cyclin-C; SRB11 homolog (hSRB11); CCNC

Background
Cyclin C is a regulatory subunit of the cyclin family that partners specifically with CDK8 (forming the CDK8/Cyclin C kinase module of the Mediator complex) and CDK3 to control transcription and cell cycle transitions, rather than the canonical G1/S progression. It contains two canonical five-helix repeats that flank a flexible N-terminal α-helix, which is short, mobile, and exposed for non-CDK interactions. This N-terminal helix docks onto CDK8's PSTAIRE helix and αC-helix, inducing the active DFG-in (DMG-in for CDK8) conformation without the need for T-loop phosphorylation. Key interaction hotspots include Glu99 of Cyclin C, which orients CDK8's conserved arginines (R158, R356, R366) and stabilizes the activation loop and αB/αC-helices through hydrogen bonding networks. The Cyclin C/CDK8 complex phosphorylates RNA polymerase II CTD at Ser2 and Ser5, MED13, and transcription factors such as STAT1 and β-catenin to repress super-enhancers, terminate Pol II pause-release, and fine-tune immediate-early gene expression. In response to stress, nuclear export releases Cyclin C to the cytosol, where it activates Drp1 and Bax for mitochondrial outer membrane permeabilization, fission, and apoptosis through synergistic PTEN, p53, and p21 signaling. Cyclin C also regulates thyroid cancer suppression, Rb-quiescence exit via CDK3, and oxidative stress responses. Its dysregulation can drive colorectal and breast cancer through Mediator hijacking, while cytosolic translocation can promote neurodegeneration and disrupt the balance of apoptosis.

Background

Cyclin C is a regulatory subunit of the cyclin family that partners specifically with CDK8 (forming the CDK8/Cyclin C kinase module of the Mediator complex) and CDK3 to control transcription and cell cycle transitions, rather than the canonical G1/S progression. It contains two canonical five-helix repeats that flank a flexible N-terminal α-helix, which is short, mobile, and exposed for non-CDK interactions. This N-terminal helix docks onto CDK8's PSTAIRE helix and αC-helix, inducing the active DFG-in (DMG-in for CDK8) conformation without the need for T-loop phosphorylation. Key interaction hotspots include Glu99 of Cyclin C, which orients CDK8's conserved arginines (R158, R356, R366) and stabilizes the activation loop and αB/αC-helices through hydrogen bonding networks. The Cyclin C/CDK8 complex phosphorylates RNA polymerase II CTD at Ser2 and Ser5, MED13, and transcription factors such as STAT1 and β-catenin to repress super-enhancers, terminate Pol II pause-release, and fine-tune immediate-early gene expression. In response to stress, nuclear export releases Cyclin C to the cytosol, where it activates Drp1 and Bax for mitochondrial outer membrane permeabilization, fission, and apoptosis through synergistic PTEN, p53, and p21 signaling. Cyclin C also regulates thyroid cancer suppression, Rb-quiescence exit via CDK3, and oxidative stress responses. Its dysregulation can drive colorectal and breast cancer through Mediator hijacking, while cytosolic translocation can promote neurodegeneration and disrupt the balance of apoptosis.

References
https://pubmed.ncbi.nlm.nih.gov/15979093/ https://pubmed.ncbi.nlm.nih.gov/33523904/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%